Theracryf Plc (TCF.L)
TCF.L Stock Price Chart
Explore Theracryf Plc interactive price chart. Choose custom timeframes to analyze TCF.L price movements and trends.
TCF.L Company Profile
Discover essential business fundamentals and corporate details for Theracryf Plc (TCF.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Oct 2015
Employees
9.00
Website
https://theracryf.comCEO
Huw Jones BSc,
Description
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
TCF.L Financial Timeline
Browse a chronological timeline of Theracryf Plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 26 Nov 2025
Earnings released on 3 Jun 2025
Earnings released on 14 May 2025
Earnings released on 28 Nov 2024
EPS came in at -£0.00.
Earnings released on 1 Nov 2024
Earnings released on 28 May 2024
Stock split effective on 26 Apr 2024
Shares were split 507:500, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2024
EPS came in at -£0.01.
Earnings released on 31 Oct 2023
EPS came in at -£0.01, while revenue for the quarter reached £396.00K.
Earnings released on 30 Sept 2023
EPS came in at -£0.01, while revenue for the quarter reached £396.00K.
Earnings released on 7 Jun 2023
Earnings released on 31 Mar 2023
EPS came in at -£0.01, while revenue for the quarter reached £442.00K.
Earnings released on 8 Dec 2022
EPS came in at -£0.01.
Earnings released on 29 Sept 2022
EPS came in at -£0.01.
Earnings released on 8 Jun 2022
Earnings released on 30 Mar 2022
EPS came in at -£0.00.
Earnings released on 7 Dec 2021
EPS came in at -£0.01.
Earnings released on 29 Sept 2021
EPS came in at -£0.01.
Earnings released on 15 Jun 2021
Earnings released on 30 Mar 2021
EPS came in at -£0.00.
Earnings released on 10 Dec 2020
EPS came in at -£0.01, while revenue for the quarter reached £194.00K.
Earnings released on 29 Sept 2020
EPS came in at -£0.01.
TCF.L Stock Performance
Access detailed TCF.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.